The Cancer Disease Deliberation Committee has settled as the highest threshold in reimbursement for anticancer drugs in Korea. This expert committee, which is a mandatory step for reimbursement in Korea, has put many anticancer drugs through an ordeal, to the extent that it was coined the ‘wailing wall’ to reimbursement in Korea.

The committee, which had originally been launched for the purpose of evaluating the clinical usefulness of anticancer drugs that applied for reimbursement listing, had become ridden with issues after additionally starting a review on each drug’s fiscal impact.

Questions were raised on what grounds the CDDC had to analyze the drug’s fiscal impact, and the fai